Check-Cap Ltd. (MBAI)

Check-Cap Ltd. is a clinical-stage medical diagnostics company specializing in capsule-based screening technology. Their primary focus is on developing a non-invasive alternative for colorectal cancer screening.

46/100 AI Score MCap 10M Vol 346K

Company Overview

CEODavid Lontini
HeadquartersIsfiya, IL
IPO Year2015

Check-Cap Ltd. (MBAI) offers a novel, non-invasive colorectal cancer screening technology, positioning it for growth in the expanding diagnostics market; however, as a clinical-stage company, it carries significant development and regulatory risk, making it a high-risk, high-reward investment.

Investment Thesis

Investing in Check-Cap Ltd. (MBAI) presents a high-risk, high-reward opportunity. The company's innovative, non-invasive colorectal cancer screening technology addresses a significant market need and has the potential to disrupt the traditional screening landscape. Successful completion of clinical trials and subsequent regulatory approvals could drive significant value appreciation. The current market capitalization of $0.01 billion reflects the inherent risks associated with a clinical-stage company. Key value drivers include positive clinical trial results, strategic partnerships for commercialization, and successful market penetration following regulatory clearance. However, investors should be aware of the substantial risks associated with clinical development, regulatory hurdles, and competition from established screening methods. The company's beta of 0.89 indicates a slightly lower volatility than the overall market.

Key Highlights

  • Check-Cap Ltd. is a clinical-stage company, meaning it currently has no revenue from product sales.
  • The company focuses on capsule-based screening technology, offering a non-invasive approach to colorectal cancer detection.
  • Check-Cap's primary focus is on colorectal cancer screening, a large and growing market.
  • The company is based in Isfiya, Israel, indicating a global perspective but also potential geographic-specific regulatory hurdles.
  • The company has a negative P/E ratio of -0.34, typical for clinical-stage companies investing heavily in R&D.

Competitors

Strengths

  • Non-invasive screening technology.
  • Potential to increase screening rates.
  • Patient-friendly alternative to colonoscopies.
  • Focus on early detection of colorectal cancer.

Weaknesses

  • Clinical-stage company with no current revenue.
  • Reliance on successful clinical trial outcomes.
  • Need for regulatory approvals.
  • Limited financial resources.

Catalysts

  • Upcoming: Announcement of clinical trial results.
  • Upcoming: Potential FDA or other regulatory approval.
  • Ongoing: Progress in securing strategic partnerships.
  • Ongoing: Development of new applications for the technology.
  • Ongoing: Increasing awareness of colorectal cancer screening.

Risks

  • Potential: Failure to achieve positive clinical trial results.
  • Potential: Delays or rejection of regulatory approvals.
  • Potential: Competition from established screening methods.
  • Ongoing: Limited financial resources and need for additional funding.
  • Ongoing: Uncertainty regarding reimbursement from insurance companies.

Growth Opportunities

  • Regulatory Approval and Commercialization: Securing regulatory approvals from agencies like the FDA in the United States and similar bodies in Europe is paramount. Successful approval would allow Check-Cap to commercialize its technology and generate revenue. The colorectal cancer screening market is substantial, estimated to be worth billions of dollars annually. Timeline: Anticipated within the next 2-3 years pending clinical trial outcomes.
  • Strategic Partnerships: Forming strategic partnerships with established medical device companies or pharmaceutical firms could accelerate the commercialization process and expand market reach. These partnerships could provide access to established distribution networks and marketing expertise. Timeline: Ongoing, with potential partnerships emerging within the next year.
  • Expansion of Product Pipeline: Expanding the application of its capsule-based technology to screen for other gastrointestinal diseases could significantly broaden Check-Cap's market opportunity. This could include screening for conditions like esophageal cancer or gastric ulcers. Timeline: Research and development efforts ongoing, with potential for new product development within the next 3-5 years.
  • Geographic Expansion: Expanding into new geographic markets, particularly in Asia and Latin America, could drive significant growth. These regions have large populations and increasing healthcare spending. Timeline: Potential expansion within the next 3-5 years, contingent on regulatory approvals and market assessments.
  • Improved Technology and Accuracy: Continuous improvement of the capsule-based technology to enhance accuracy and reduce false positive/negative rates is crucial for maintaining a competitive edge. This could involve incorporating advanced imaging techniques or artificial intelligence algorithms. Timeline: Ongoing research and development efforts.

Opportunities

  • Growing demand for non-invasive screening methods.
  • Strategic partnerships with established companies.
  • Expansion into new geographic markets.
  • Development of new applications for capsule-based technology.

Threats

  • Competition from established screening methods.
  • Regulatory hurdles and delays.
  • Technological advancements by competitors.
  • Reimbursement challenges from insurance companies.

Competitive Advantages

  • Proprietary capsule-based screening technology.
  • Potential for strong intellectual property protection through patents.
  • First-mover advantage in the non-invasive colorectal cancer screening market.
  • Established clinical data supporting the efficacy of their technology.

About

Check-Cap Ltd., founded in 2004 and based in Isfiya, Israel, is a clinical-stage medical diagnostics company dedicated to transforming colorectal cancer screening through innovative, capsule-based technology. Recognizing the limitations and patient reluctance associated with traditional screening methods like colonoscopies, Check-Cap has focused on developing a more patient-friendly and accessible alternative. The company's primary product is a non-invasive screening system designed to detect precancerous polyps and early-stage cancer. This system utilizes a small, ingestible capsule that transmits data to an external recording device, eliminating the need for bowel preparation or sedation. While still in the clinical stage, Check-Cap's technology holds the potential to significantly increase screening rates and improve early detection of colorectal cancer, addressing a critical unmet need in preventative healthcare. The company's focus remains on achieving regulatory approvals and commercializing its technology to make a meaningful impact on colorectal cancer outcomes.

What They Do

  • Develop capsule-based screening technology.
  • Focus on non-invasive colorectal cancer screening.
  • Create an ingestible capsule that transmits data externally.
  • Offer an alternative to traditional colonoscopies.
  • Aim to improve early detection of colorectal cancer.
  • Conduct clinical trials to validate their technology.
  • Seek regulatory approvals for commercialization.

Business Model

  • Develop and manufacture capsule-based screening systems.
  • Generate revenue through the sale of screening capsules and related equipment.
  • Potentially offer service contracts for data analysis and reporting.
  • Seek partnerships with healthcare providers and insurance companies for reimbursement.

Industry Context

Check-Cap operates within the medical diagnostics industry, specifically targeting the colorectal cancer screening market. This market is characterized by a growing demand for non-invasive and patient-friendly screening methods. The competitive landscape includes established players offering traditional screening methods like colonoscopies and fecal occult blood tests, as well as emerging companies developing alternative screening technologies. Check-Cap's capsule-based technology aims to differentiate itself by offering a convenient and accurate screening option that can potentially increase screening rates and improve early detection. The overall medical diagnostics market is expected to continue growing, driven by factors such as an aging population, increasing awareness of preventative healthcare, and advancements in technology.

Key Customers

  • Patients at risk for colorectal cancer.
  • Gastroenterologists and other healthcare providers.
  • Hospitals and clinics.
  • Insurance companies and healthcare payers.
AI Confidence: 69% Updated: 2/3/2026

Financials

Chart & Info

Price Chart

Check-Cap Ltd. (MBAI) stock price: $1.68 (-0.21, -11.11%)

Why Bull

  • •MBAI's insider activity suggests confidence; recent buys could signal positive internal expectations.
  • •The community's bullish sentiment seems to be building, possibly driven by perceived undervaluation or upcoming catalysts.
  • •Market perception indicates growing interest in MBAI's sector, which could create tailwinds for the stock.
  • •Bullish voices highlight potential breakthroughs in Check-Cap's technology, suggesting a positive long-term outlook.

Why Bear

  • •Recent insider selling, even if for personal reasons, can create negative sentiment and raise concerns.
  • •Bearish community members express doubts about MBAI's ability to compete effectively in a crowded market.
  • •Market perception reveals concerns about regulatory hurdles impacting Check-Cap's product approval timeline.
  • •Bearish sentiment emphasizes the company's cash burn rate and potential need for further dilution, creating uncertainty.

Latest News

Technical Analysis

RSI(14)
--
MACD
--
Volume
345,431

Rationale

AI-generated technical analysis for MBAI including trend direction, momentum, and pattern recognition.

What to Watch

Key support and resistance levels, volume signals, and upcoming events.

Risk Management

Position sizing, stop-loss levels, and risk-reward assessment.

Community

Discussion

Share your analysis and discuss Check-Cap Ltd. (MBAI) with other investors. Log in to post.

Sentiment

Community sentiment and discussion activity for MBAI.

Make a Prediction

Set your price target for Check-Cap Ltd. (MBAI), choose a timeframe, and track your prediction accuracy.

Current price: $1.68

Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MBAI.

Price Targets

Wall Street price target analysis for MBAI.

Insider Flow (30d)

No insider trades in the last 30 days.

MoonshotScore

45.5/100

Score Factors

  • Revenue Growth 5/100

    Revenue growth data is currently unavailable for this company.

  • Gross Margin 5/100

    Gross margin data is currently unavailable for this company.

  • Operating Leverage 4/100

    Limited operating leverage due to slower revenue growth, keeping profit scaling constrained.

  • Cash Runway 5/100

    Cash position data is currently unavailable for this company.

  • R&D Intensity 5/100

    R&D spending data is currently unavailable for this company.

  • Insider Activity 6/100

    No significant insider buying or selling recently, which is neutral for the stock outlook.

  • Short Interest 5/100

    Float and volume data unavailable for liquidity analysis.

  • Price Momentum 0/100

    No bullish technical signals detected. The stock lacks upward price momentum currently.

  • News Sentiment 5/100

    No sentiment data available

What does this score mean?

The MoonshotScore rates MBAI's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.

Frequently Asked Questions

What does Check-Cap Ltd. Ordinary Share do?

Check-Cap Ltd. is a clinical-stage medical diagnostics company focused on developing and commercializing capsule-based screening technology. Their primary focus is on providing a non-invasive alternative for colorectal cancer screening. The company's technology involves an ingestible capsule that transmits data to an external recording device, allowing for the detection of precancerous polyps and early-stage cancer without the need for bowel preparation or sedation. Check-Cap aims to improve early detection rates and patient compliance by offering a more convenient and patient-friendly screening option, ultimately reducing the incidence and mortality associated with colorectal cancer.

Is MBAI stock a good buy?

Evaluating MBAI stock requires careful consideration of its high-risk, high-reward profile. As a clinical-stage company, Check-Cap's value is primarily based on the potential of its technology and future regulatory approvals. The absence of current revenue and the inherent uncertainties of clinical trials make it a speculative investment. However, successful commercialization of its non-invasive colorectal cancer screening technology could lead to significant returns. Investors should assess their risk tolerance and conduct thorough due diligence before investing, considering factors such as clinical trial progress, regulatory landscape, and competitive environment. The current market capitalization of $0.01 billion reflects the substantial risks involved.

What are the main risks for MBAI?

Investing in Check-Cap Ltd. (MBAI) carries significant risks inherent to clinical-stage medical device companies. The primary risk is the potential failure to achieve positive clinical trial results, which could jeopardize regulatory approvals and commercialization prospects. Regulatory hurdles and delays also pose a substantial risk, as the company's success depends on obtaining clearances from agencies like the FDA. Competition from established screening methods and emerging technologies could limit market share. Furthermore, Check-Cap's limited financial resources and reliance on additional funding raise concerns about its ability to sustain operations and execute its business plan. Uncertainty regarding reimbursement from insurance companies adds another layer of risk, as widespread adoption of the technology depends on favorable reimbursement policies.

Is MBAI a good stock to buy?

Whether MBAI is a good investment depends on your financial goals, risk tolerance, and investment horizon. Key factors to evaluate include the company's revenue growth trajectory, profit margins, debt-to-equity ratio, competitive moat, and valuation multiples (P/E, P/S, EV/EBITDA) relative to industry peers. Our AI-generated Investment Thesis and SWOT analysis on this page provide a data-driven starting point. Always do your own research and consider consulting a financial advisor before making investment decisions.

What is the MBAI MoonshotScore?

The MoonshotScore for MBAI is an AI-powered rating from 0 to 100 that evaluates a stock across four dimensions: growth potential (revenue and earnings trajectory), financial health (balance sheet strength, cash flow), market momentum (price trends, volume patterns, institutional flows), and risk factors (volatility, debt levels, sector headwinds). Scores above 70 indicate strong potential, 50-70 moderate, and below 50 suggests caution. The score is recalculated daily using the latest financial data and market signals.

How often is MBAI data updated?

MBAI stock prices are updated in real-time during U.S. market hours (9:30 AM - 4:00 PM ET, Monday through Friday). After-hours and pre-market prices are also tracked. Company fundamentals (earnings, revenue, balance sheet) are refreshed when new quarterly or annual reports are filed. Analyst ratings, price targets, and AI-generated insights are updated daily. Breaking news related to MBAI is aggregated continuously from premium financial news sources throughout the day.

What are the growth catalysts for MBAI?

Growth catalysts for Check-Cap Ltd. (MBAI) can include several categories: product catalysts (new launches, FDA approvals, patent grants), financial catalysts (earnings beats, margin expansion, share buybacks), strategic catalysts (acquisitions, partnerships, market expansion into new regions), and macro catalysts (favorable regulation, industry tailwinds, secular growth trends). Our AI analyzes Check-Cap Ltd.'s specific catalysts using earnings transcripts, SEC filings, and news sentiment to identify the most impactful near-term and long-term drivers.

Who are MBAI's main competitors?

Check-Cap Ltd. (MBAI) competes with companies in its industry that target similar customers, markets, or product categories. Competitor analysis involves comparing key metrics: market share, revenue growth rates, profit margins, R&D spending, and valuation multiples. Understanding competitive positioning helps investors assess whether MBAI has a sustainable competitive advantage (moat) through brand strength, network effects, cost leadership, or switching costs. Our Competitors section provides a side-by-side comparison with relevant peers.

What do analysts say about MBAI?

Wall Street analyst coverage for MBAI includes consensus ratings (buy, hold, or sell), 12-month price targets, and earnings estimates. Analyst opinions are aggregated from major investment banks and research firms. Key metrics to watch include the consensus price target (average, high, and low estimates), the number of analysts covering the stock, any recent rating changes (upgrades or downgrades), and how actual earnings compare to analyst estimates (beat or miss history). Our platform aggregates these from multiple data providers for a comprehensive view.

What is MBAI's market cap?

Market capitalization (market cap) for MBAI is calculated by multiplying the current share price by the total number of outstanding shares. It represents the market's total valuation of the company. Stocks are typically categorized as mega-cap ($200B+), large-cap ($10B-$200B), mid-cap ($2B-$10B), small-cap ($300M-$2B), or micro-cap (under $300M). Market cap influences index inclusion, institutional ownership eligibility, and risk profile. Our Key Statistics section shows MBAI's current market cap alongside enterprise value and other valuation metrics.

How has MBAI stock performed recently?

MBAI's recent stock performance can be evaluated across multiple timeframes: daily price changes, week-over-week momentum, monthly trends, and year-to-date returns. Important performance indicators include the stock's 52-week high and low, moving averages (50-day and 200-day SMA), relative strength index (RSI), and volume trends. Comparing MBAI's performance against its sector index and the S&P 500 provides context on whether it is outperforming or underperforming the broader market.

What are the risks of investing in MBAI?

Key risk categories for MBAI include: market risk (overall market downturns affecting stock prices), company-specific risk (management changes, product failures, competitive threats), financial risk (high debt levels, cash burn, dilution from stock issuance), regulatory risk (government policy changes, lawsuits, compliance issues), and macroeconomic risk (interest rate changes, inflation, currency fluctuations). Beta measures MBAI's volatility relative to the market - a beta above 1.0 means higher volatility than the S&P 500. Our AI-generated risk assessment identifies the most relevant risk factors for this specific stock.

Are insiders buying or selling MBAI?

Insider trading activity for MBAI tracks purchases and sales by company executives, directors, and major shareholders (10%+ owners) as reported in SEC Form 4 filings. Insider buying is generally considered a bullish signal because insiders have the deepest knowledge of company operations, while selling may have various motivations (diversification, tax planning, pre-planned 10b5-1 trading plans). Key metrics include the buy-to-sell ratio, total dollar value of insider transactions, and whether multiple insiders are trading in the same direction. Our Insider Flow tab shows recent transactions with dates and dollar amounts.

Is MBAI a good stock for beginners?

Check-Cap Ltd. (MBAI) can be suitable for beginner investors depending on several factors. Look at the MoonshotScore on this page for an overall AI-powered assessment of growth potential and risk. Beginners should also check the company's market cap (larger companies tend to be less volatile), gross margin (higher margins mean stronger business fundamentals), and cash position (healthy cash reduces bankruptcy risk). Always start with a small position size and never invest money you cannot afford to lose.

How risky is MBAI for first-time investors?

Every stock carries risk, including Check-Cap Ltd. (MBAI). First-time investors should review the Risk Factors section on this page for company-specific risks. Key risk indicators include price volatility (check the chart for daily swings), insider selling activity (see Insider Flow tab), and cash runway (see MoonshotScore breakdown). A diversified portfolio with an index fund like the S&P 500 as a core holding is generally recommended before adding individual stocks like MBAI.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Data provided for informational purposes only.

AI Analysis Notes
  • Information is based on publicly available sources and may be subject to change.
  • Investment decisions should be based on individual risk tolerance and thorough due diligence.
Data Sources
profilefundamentalsexistingCopy